Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
International Journal of MS Care
|
September 18, 2023
Assessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients With Multiple Sclerosis
Caspar E P van Munster, Burggraaff Jessica, Saskia Steinheimer, et al.
International Journal of MS Care
|
September 12, 2022
Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures
Ka-Hoo Lam, Caspar E P van Munster, Marcus D'Souza, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
January 31, 2018
Disease activity following pregnancy-related discontinuation of natalizumab in MS
Iris Kleerekooper, Zoé L E van Kempen, Cyra E Leurs, et al.
Multiple Sclerosis and Related Disorders
|
June 15, 2026
Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis
P C G Molenaar, D L Weir, E P J Arnoldus, et al.
Journal of Neurology
|
July 23, 2025
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)
W H Fung, M H J Wessels, E M E Coerver, et al.
JAMA Neurology
|
December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial
Eline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Liza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
European Journal of Neurology
|
July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab
Laura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
BMC Surgery
|
March 17, 2009
Transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND-study)
Frank J C van den Broek, Eelco J R de Graaf, Marcel G W Dijkgraaf, et al.
Journal of the Neurological Sciences
|
June 26, 2024
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial
A A Toorop, M H J Wessels, L M Y Gelissen, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
International Journal of MS Care
|
September 18, 2023
Assessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients With Multiple Sclerosis
Caspar E P van Munster, Burggraaff Jessica, Saskia Steinheimer, et al.
International Journal of MS Care
|
September 12, 2022
Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures
Ka-Hoo Lam, Caspar E P van Munster, Marcus D'Souza, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
January 31, 2018
Disease activity following pregnancy-related discontinuation of natalizumab in MS
Iris Kleerekooper, Zoé L E van Kempen, Cyra E Leurs, et al.
Multiple Sclerosis and Related Disorders
|
June 15, 2026
Real world drug utilization patterns in the first years following a relapsing-remitting multiple sclerosis diagnosis
P C G Molenaar, D L Weir, E P J Arnoldus, et al.
Journal of Neurology
|
July 23, 2025
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)
W H Fung, M H J Wessels, E M E Coerver, et al.
JAMA Neurology
|
December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial
Eline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Liza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
European Journal of Neurology
|
July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab
Laura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
BMC Surgery
|
March 17, 2009
Transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND-study)
Frank J C van den Broek, Eelco J R de Graaf, Marcel G W Dijkgraaf, et al.
Journal of the Neurological Sciences
|
June 26, 2024
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial
A A Toorop, M H J Wessels, L M Y Gelissen, et al.
Page
of 4